Stocks close lower, major averages on pace for weekly declines as recession

Markets will face recession 'decision time' once it hits prior lows, says SoFi's Liz Young

Stocks fell for a third straight day Thursday following the Federal Reserve’s aggressive rate hike, as investors increasingly fear the central bank will push the economy into a recession as it battles to curb rising inflation.

All the major averages finished Thursday’s session on pace to close the week with losses. The Dow is down about 2.42%, while the S&P and Nasdaq have tumbled 2.98% and 3.33%, respectively. The S&P and Dow closed Thursday 2.5% and 0.5% off their recent closing lows.

The S&P 500 slid 0.84% to 3,757.99, while the Nasdaq Composite shed 1.37% to 11,066.81. The Dow Jones Industrial Average closed 107.10 points lower, or 0.35%, at 30,076.68.

Bond yields surged again on Thursday, with the yields on the 10-year and 2-year Treasury notes notching fresh multiyear highs, hitting their highest levels since February 2011 and October 2007, respectively.

Thursday moves came after the Fed on Wednesday maintained its aggressive stance, enacting another 75 basis point hike and predicting bringing short-term rates as high as 4.4% by the end of 2022. Other central banks worldwide followed the Fed’s lead, implementing their own sizeable hikes overnight despite potential repercussions for the economy.

Growth-oriented tech stocks and semiconductors took a leg lower on Thursday amid fears of slowing economic growth. Industrials and consumer discretionary were the worst-performing S&P 500 sectors, losing about 1.5% and 2.2%, respectively, because of their reliance on the economy.

“The Fed’s paved the way for much of the world to continue with aggressive rate hikes, and that’s going to lead to a global recession, and how severe it is will be determined on how long it takes inflation to come down,” said Ed Moya, a senior market analyst at Oanda.

Defensive stocks outperformed with drugmakers and consumer staples in the green on Thursday. Eli Lilly shares gained 4% after UBS upgraded the stock and said it could be developing the biggest drug ever.

Read More: Stocks close lower, major averages on pace for weekly declines as recession

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.